stoxline Quote Chart Rank Option Currency Glossary
  
Omeros Corporation (OMER)
3.215  -0.735 (-18.61%)    05-16 16:00
Open: 3.925
High: 3.9313
Volume: 2,998,859
  
Pre. Close: 3.95
Low: 2.97
Market Cap: 187(M)
Technical analysis
2025-05-16 4:42:24 PM
Short term     
Mid term     
Targets 6-month :  6.86 1-year :  8.95
Resists First :  5.87 Second :  7.67
Pivot price 5.82
Supports First :  2.97 Second :  2.47
MAs MA(5) :  3.86 MA(20) :  6.13
MA(100) :  8.12 MA(250) :  6.27
MACD MACD :  -1 Signal :  -0.7
%K %D K(14,3) :  4.7 D(3) :  6.6
RSI RSI(14): 23.3
52-week High :  13.6 Low :  2.97
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ OMER ] has closed above bottom band by 5.0%. Bollinger Bands are 120.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.94 - 3.96 3.96 - 3.98
Low: 2.93 - 2.95 2.95 - 2.97
Close: 3.18 - 3.22 3.22 - 3.24
Company Description

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Headline News

Fri, 16 May 2025
Omeros Corp. Earnings Call: Cautious Optimism Amid Challenges - TipRanks

Fri, 16 May 2025
Omeros Corporation to acquire $80.5 million of its convertible senior notes due 2026 - MSN

Fri, 16 May 2025
Omeros: Q1 Earnings Snapshot - CT Insider

Fri, 16 May 2025
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... - Yahoo Finance

Fri, 16 May 2025
Omeros Corporation Reports Q1 2025 Financial Results - TipRanks

Thu, 15 May 2025
Omeros (OMER) Streamlines Debt, Preps for Narsoplimab Launch - GuruFocus

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 58 (M)
Shares Float 55 (M)
Held by Insiders 4.4 (%)
Held by Institutions 46.1 (%)
Shares Short 9,170 (K)
Shares Short P.Month 9,330 (K)
Stock Financials
EPS -3.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -3.16
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -32.3 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -1.23
Sales Per Share 0
EBITDA (p.s.) -2.89
Qtrly Earnings Growth 0 %
Operating Cash Flow -149 (M)
Levered Free Cash Flow -115 (M)
Stock Valuations
PE Ratio -1.03
PEG Ratio 0
Price to Book value -1.03
Price to Sales 0
Price to Cash Flow -1.26
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android